These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 12857372)

  • 21. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
    Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
    Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy.
    Bensinger WI; Buckner CD; Shannon-Dorcy K; Rowley S; Appelbaum FR; Benyunes M; Clift R; Martin P; Demirer T; Storb R; Lee M; Schiller G
    Blood; 1996 Dec; 88(11):4132-8. PubMed ID: 8943847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
    Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
    Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unrelated donor transplantation after reduced intensity conditioning as an approach for patients lacking related donors for allogeneic stem cell transplantation.
    Hoepfner S; Goerner M; Benner A; Henning P; Ho AD
    J Hematother Stem Cell Res; 2003 Jun; 12(3):331-9. PubMed ID: 12857374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
    Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
    Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
    O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
    Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation.
    Nachbaur D; Eibl B; Kropshofer G; Meister B; Mitterschiffthaler A; Schennach H; Fischer G; Kopp M; Gunsilius E; Gastl G
    J Hematother Stem Cell Res; 2002 Aug; 11(4):731-7. PubMed ID: 12201962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
    Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
    Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.
    Baron F; Maris MB; Storer BE; Sandmaier BM; Panse JP; Chauncey TR; Sorror M; Little MT; Maloney DG; Storb R; Heimfeld S
    Leukemia; 2005 May; 19(5):822-8. PubMed ID: 15772701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
    Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
    Maris MB; Niederwieser D; Sandmaier BM; Storer B; Stuart M; Maloney D; Petersdorf E; McSweeney P; Pulsipher M; Woolfrey A; Chauncey T; Agura E; Heimfeld S; Slattery J; Hegenbart U; Anasetti C; Blume K; Storb R
    Blood; 2003 Sep; 102(6):2021-30. PubMed ID: 12791654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.